Par Pharmaceutical Companies ( PRX ) Q4 2012 Earnings Call ..... gentlemen, and welcome to the Par Pharmaceutical Companies Inc. Earnings Conference ..... article/1292521- par - pharmaceutical - companies -management-discusses
Good day, ladies and gentlemen, and welcome to the Par Pharmaceutical Companies , Inc. Earnings Conference Call. My name is Kasiv, and I will be your operator for today. At this time, all participants are
Protalix BioTherapeutics ( PLX +0.7% ) says its the first patient has been treated in its Phase I/II clinical trials of PRX -102, its plant cell-expressed, chemically modified enzyme replacement therapy for the treatment of Fabry disease. Post your comment!
yesterday received FTC permission for the deal, adding to EU authorization earlier this month. Under the conditions of the approval, Watson must sell 14 generic drugs to Par Pharmaceuticals ( PRX ) and four to Sandoz. ( PR ) Post your comment!
Sept 18 (Reuters) - Par Pharmaceutical Companies , Inc. on Tuesday sold $490 million of senior ..... bookrunning managers for the sale. BORROWER: PAR PHARMACEUTICAL COMPANIES , INC. AMT $490 MLN COUPON 7.375 PCT MATURITY
preliminary 'B+' corporate credit rating, on Woodcliff Lake, N.J.-based pharmaceutical company Par Pharmaceutical Companies Inc. remain unchanged following a change to deal terms. The changes include the $75 million upsize to
IPCI has a strategic alliance (10-year profit sharing agreement that begins with first sales of the drug) with Par Pharma ( PRX ), which agreed to a buyout by private equity firm TPG last month in a $1.9 billion deal. IPCI has settled patent litigation
By Kapitall : Do you prefer to invest with a stock's trading momentum? We ran a screen with that idea in mind. We began by screening the drugmakers industry for stocks with strong momentum, trading within 5% of their 52-week highs. We then screened for those stocks with strong sales trends, ...
Par Pharmaceuticals PRX reported strong revenue growth and margin expansion during the second quarter thanks primarily to its limited competition launch
A very good day to you, ladies and gentlemen, and welcome to the Par Pharmaceutical Second Quarter Earnings Conference Call. My name is Mansi, and I ll be your operator for today. At this time, all participants are in listen-only mode. We will conduct a QnA session towards the end of this ...